Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$3.69M+456.80%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Brian J. Kieser
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 19
- Beta
- 0.80
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -1.69
Financials
Revenue
$3.69M+456.8%Net Income
$-3.63MEBITDA
$-398.0KFree Cash Flow
$-2.27M-3347.1%EPS (diluted)
$-8.07Shares Outstanding (diluted)
450.7K+719.1%Operating Expenses
$3.61MCash & Debt
$492.0KReturn of Capital
$0.00Revenue by Segment (annual)
$2.22MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $11.42M | $-3.00M | $-7.64 |
| 2024 | $8.69M | $-3.28M | $-10.08 |
| 2023 | $4.09M | $-3.16M | $-11.13 |
| 2022 | $2.05M | $-4.75M | $-17.03 |
| 2021 | $1.55M | $-4.31M | $-28.93 |
| 2020 | $674.0K | $-2.26M | $-20.09 |
| 2019 | $717.0K | $-1.92M | $-99.19 |
| 2018 | $2.21M | $-1.89M | $0.00 |
| 2017 | $1.99M | $-953.0K | $0.00 |
| 2016 | $2.15M | $-1.78M | $0.00 |
Valuation
NXGLhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80-20.00%Social Signal Score
Mentions (6)
- Newsglobenewswire.com·3d ago·Negative
…al Results and Corporate Update Conference Call to November 24th LANGHORNE, Pa., Nov. 19, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a company with a patient centric medical technology sales and marketing team working closely with clinicians to provide solutions that drive better outcomes, streamline care, and elevate the patient experience, today announced that it has postponed its conference call to discuss its financial results for the third quarter en…
View source ↗ - Newsglobenewswire.com·11d ago·Neutral
NEXGEL Announces Noteholder Participation in Strategic Recapitalization and Approximately $1.2 Million in New Capital Funding Approximately 95% of Outstanding Convertible Note Principal Committed to Conversion, Subject to Completion of a Strategic Merger
View source ↗ - Newsglobenewswire.com·26d ago·Positive
NEXGEL Regains Compliance with Nasdaq Listing Requirement LANGHORNE, Pa., Oct. 27, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a company with a patient-centric medical technology sales and marketing team working closely with clinicians to provide solutions that drive better outcomes, streamline care and elevate the patient experience, today announced that it has received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Mar…
View source ↗ - Newsseekingalpha.com·58d ago·Positive
NEXGEL, Inc. (NXGL) Discusses Strategic Platform Reorganization and Refocus on Medical Device and Biomedical Innovation Transcript NEXGEL, Inc. (NXGL) Discusses Strategic Platform Reorganization and Refocus on Medical Device and Biomedical Innovation Transcript
View source ↗ - Newsglobenewswire.com·60d ago·Neutral
NEXGEL Announces Dial-In Details for Investor Update Call LANGHORNE, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a company with a patient centric medical technology sales and marketing team working closely with clinicians to provide solutions that drive better outcomes, streamline care, and elevate the patient experience, today announced dial-in details for its previously announced investor update call to be held on September 24, 2026, at 4:…
View source ↗ - Newsglobenewswire.com·67d ago·Neutral
NEXGEL Announces Date for Investor Update Call LANGHORNE, Pa., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a company with a patient centric medical technology sales and marketing team working closely with clinicians to provide solutions that drive better outcomes, streamline care, and elevate the patient experience, today announced the date for the investor update call referenced in its August 17, 2026 earnings release, at which time the Company …
View source ↗
Earnings
Typical surprise +55.0% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-8.00 vs $-2.40miss
- Wed, May 13$-2.20 vs $-1.40miss
- Tue, Mar 31$-0.11 vs $-1.80beat
- Wed, Nov 12$-0.08 vs $-1.60beat
- Tue, Aug 12$-0.09 vs $-0.20beat
- Tue, May 13$-0.09 vs $-1.40beat
Estimates and results for NXGL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NXGL officers and directors.
- Bought
- $2.2m
- Sold
- $245k
24 trades
35 trades
- Levy Adam R.sold
- Levy Adam R.sold
- Levy Adam R.sold
- Levy Adam R.sold
- Levy Adam R.sold
- Levy Adam R.sold
- Levy Adam R.sold
- Levy Adam R.sold
41 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in NXGL.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
